What is the difference between retatrutide and Wegovy?

Wegovy is semaglutide (2.4 mg, Novo Nordisk), a selective GLP-1 receptor agonist FDA-approved for chronic weight management in adults with obesity. Retatrutide is an investigational triple agonist (Eli Lilly) that activates GIP, GLP-1, and glucagon receptors simultaneously. In Phase 3 data, the triple-receptor mechanism translates to approximately double the weight reduction: STEP-1 (Wegovy) ~14.9% at 68 weeks vs TRIUMPH-4 (retatrutide) ~28.7% at 68 weeks. They are different molecules in different regulatory stages. Research comparison only.

Is retatrutide stronger than Wegovy?

In terms of Phase 3 efficacy data at comparable timepoints, yes — TRIUMPH-4 (retatrutide, ~28.7% at 68 weeks) substantially exceeds STEP-1 (Wegovy, ~14.9% at 68 weeks). The mechanistic explanation is the additional GIP and glucagon receptor arms, which add insulin potentiation and thermogenesis on top of GLP-1R appetite suppression. However, Wegovy has years of real-world safety data across millions of patients; retatrutide's safety profile is still being characterized in Phase 3. This is a research-pharmacology comparison, not a clinical recommendation.

Can retatrutide replace Wegovy?

No — and this page does not suggest that. Wegovy is an FDA-approved prescription medication. Retatrutide is an investigational compound that Titan supplies as a research-use-only lyophilized vial for in-vitro laboratory research. They are in different regulatory categories and different supply channels. Any weight management treatment decision is a clinical matter between a patient and their prescribing physician.

Does Titan sell Wegovy?

No. Titan Peptide Lab does not stock semaglutide in any formulation (Ozempic, Wegovy, Rybelsus). Titan supplies retatrutide as a research-use-only lyophilized vial ($199.99) for laboratory research purposes. Wegovy is available as an FDA-approved prescription medication through licensed pharmacies and prescribers.

What comes after Wegovy — is retatrutide next?

From a pharmacology perspective, retatrutide represents the next generation of incretin receptor targeting beyond Wegovy: from single GLP-1R (semaglutide/Wegovy) to dual GLP-1R+GIPR (tirzepatide/Zepbound) to triple GLP-1R+GIPR+GcgR (retatrutide). As of July 2026, retatrutide Phase 3 results are announced and Eli Lilly has Breakthrough Therapy Designation, but no NDA has been filed. FDA approval timeline if pursued would be an additional 1–2 years. Titan supplies retatrutide now as an investigational research compound for in-vitro study only.

Retatrutide vs Wegovy · triple agonist vs obesity-approved GLP-1 · research use only

Retatrutide vs Wegovy — triple GIP/GLP-1/glucagon agonist versus obesity-approved semaglutide.

Wegovy is the Novo Nordisk brand name for semaglutide at 2.4 mg — the only dose and indication specifically approved by FDA (June 2021) for chronic weight management in adults with obesity or overweight with at least one weight-related condition. The STEP clinical program established Wegovy as the first GLP-1 agent to deliver double-digit percentage weight loss in a large Phase 3 trial: STEP-1 (Wilding et al. NEJM 2021;384:989-1002, n=1,961, 68 weeks) reported a mean −14.9% body weight versus −2.4% placebo, with 86.4% of participants achieving ≥5% weight loss. Retatrutide is the next step in incretin receptor expansion: a triple GIP/GLP-1/glucagon receptor agonist in Phase 3 trials (Eli Lilly), with TRIUMPH-4 (published December 2025) reporting ~28.7% mean weight loss at 68 weeks — nearly double Wegovy's STEP-1 result using a comparable timepoint. This page is a research-context pharmacology comparison. Titan does not sell Wegovy (semaglutide) and does not position retatrutide as a substitute for any prescribed obesity treatment. Research use only.

Retatrutide research vial — $199.99 Retatrutide mechanism explained

Receptor profile: one receptor (Wegovy) vs three (retatrutide)

Wegovy (semaglutide) activates a single receptor: GLP-1R. That one receptor drives the entire weight-loss mechanism — appetite suppression via hypothalamic GLP-1R, delayed gastric emptying, and glucose-dependent insulin potentiation. Semaglutide's selectivity is intentional: the original design goal was to avoid the side effects (nausea, hypoglycemia) associated with less selective GLP-1 compounds. Retatrutide adds GIP receptor agonism (~8.9× relative potency) and glucagon receptor agonism (~0.3× relative potency) on top of GLP-1R activation. GIP adds a second insulin-potentiation axis and may mitigate some GLP-1-mediated nausea. Glucagon adds thermogenesis and energy expenditure — a mechanism entirely absent in Wegovy. The three-receptor combination is the pharmacological reason for the ~2× efficacy difference observed in clinical data.

Retatrutide mechanism in detail →

STEP-1 vs TRIUMPH-4: head-to-body-weight data

STEP-1 (semaglutide 2.4 mg, 68 weeks, n=1,961): −14.9% mean body weight. 86.4% achieved ≥5% weight loss; 69.1% achieved ≥10%; 50.5% achieved ≥15%. TRIUMPH-4 (retatrutide, 68 weeks, published December 2025): approximately −28.7% mean body weight at the highest dose. TRIUMPH-1 (retatrutide, n=2,339, 104 weeks, published May 2026): up to approximately −30% at 104 weeks. These are not head-to-head trials and the populations and titration regimens differ, but the 68-week timepoint allows the closest comparison. The consistent ~2× magnitude gap across these timepoints maps to the receptor-targeting step-up: semaglutide adds GLP-1 only; retatrutide adds GIP and glucagon on top.

TRIUMPH Phase 3 timeline →

Pharmacokinetics: both weekly, similar half-lives

Semaglutide (Wegovy) uses a C18 fatty diacid (palmitic acid derivative) attached at Lys26 to enable albumin binding and extend the plasma half-life to approximately 7 days — once-weekly dosing with ~5 weeks to steady state. Retatrutide uses a C20 fatty diacid (eicosanedioic acid derivative) at Lys26 (a different position from the semaglutide modification) to achieve a ~6-day half-life and once-weekly dosing. Both are acylated GLP-1R/multi-receptor agonists with comparable dosing intervals. The acylation strategy is similar in concept but the chain length, attachment chemistry, and resulting multi-receptor selectivity differ.

Retatrutide half-life →

Tolerability and adverse events

Wegovy STEP-1 GI adverse events: nausea 44.2% vs 16.1% placebo; diarrhea 32.3% vs 14.5%; vomiting 24.5% vs 6.8%. Most GI events were mild-to-moderate and peaked during titration. Retatrutide Phase 2 (Jastreboff NEJM 2023;389:514-526): nausea approximately 28% — lower than Wegovy's 44% despite producing greater weight loss. The proposed mechanism is GIP receptor agonism counteracting some GLP-1-driven nausea, a hypothesis also supported by tirzepatide's comparatively better GI tolerability vs semaglutide. Retatrutide introduces a safety signal not present in Wegovy: dose-dependent heart rate elevation from glucagon receptor activation, which is being characterized in the TRIUMPH cardiovascular safety data.

Retatrutide side effects reference →

Approval status: Wegovy is approved, retatrutide is investigational

Wegovy received FDA approval for chronic weight management in June 2021 — the first new obesity medication to demonstrate >10% weight loss in a Phase 3 trial. It is a prescription medication available through licensed prescribers and pharmacies. Retatrutide is investigational — Phase 3 is complete or ongoing as of July 2026, Eli Lilly has announced Breakthrough Therapy Designation, and no NDA has been filed with FDA. Titan Peptide Lab supplies retatrutide as a research-use-only lyophilized vial ($199.99) for in-vitro laboratory research purposes only — an entirely different supply channel from the prescription obesity-treatment space.

Retatrutide RUO vial →

Why researchers compare retatrutide to Wegovy specifically

Wegovy (not Ozempic) is the correct semaglutide reference for obesity and body weight research because it is the obesity-indication brand at the 2.4 mg dose used in STEP trials. Ozempic is the lower-dose diabetes brand. When researchers benchmark retatrutide efficacy against a GLP-1-only baseline for weight-loss endpoints, Wegovy/STEP-1 at 2.4 mg is the most directly comparable reference. The comparison is pharmacological context, not a clinical recommendation. Neither compound is evaluated here as a treatment for any condition.

Incretin peptides for obesity research →

The detail, in plain terms

Retatrutide vs Wegovy — side-by-side.

Research-use comparison. All data from peer-reviewed Phase 3 publications. Retatrutide: investigational. Wegovy: FDA-approved for chronic weight management — Titan does not stock it.

Active molecule: Retatrutide: LY3437943 (Eli Lilly). Wegovy: semaglutide 2.4 mg (Novo Nordisk).
Receptor target(s): Retatrutide: GIP + GLP-1 + Glucagon (triple). Wegovy: GLP-1R only (single).
GIP receptor: Retatrutide: YES (~8.9× potency). Wegovy: NO.
Glucagon receptor: Retatrutide: YES (~0.3×; thermogenesis). Wegovy: NO.
Half-life / dosing: Retatrutide: ~6 days; weekly (C20 fatty diacid at Lys26). Wegovy: ~7 days; weekly (C18 fatty diacid).
Phase 3 weight loss (68wk): Retatrutide: TRIUMPH-4 ~28.7%. Wegovy: STEP-1 ~14.9% (Wilding NEJM 2021).
Nausea rate: Retatrutide Phase 2: ~28%. Wegovy STEP-1: ~44% vs 16% placebo.
Heart rate signal: Retatrutide: dose-dependent elevation (glucagon arm). Wegovy: minimal.
FDA status: Retatrutide: investigational / Breakthrough Therapy / NDA not filed (Jul 2026). Wegovy: approved Jun 2021 (chronic weight management).
Titan supply: Retatrutide: lyophilized research vial, RUO, $199.99. Wegovy: NOT stocked by Titan.

head-to-head

Retatrutide vs Wegovy — receptor and trial data

Pharmacology and Phase 3 efficacy context. Research use only.

Criterion	Retatrutide	Wegovy (semaglutide 2.4 mg)
Receptor target(s)	GIP + GLP-1 + Glucagon (triple)	GLP-1R only (single)
Drug class	Triple incretin agonist (investigational)	GLP-1 receptor agonist (approved)
Half-life	~6 days (weekly)	~7 days (weekly)
Phase 3 weight loss (68wk)	~28.7% (TRIUMPH-4 2025)	~14.9% (STEP-1 2021)
Nausea	~28% Phase 2	~44% STEP-1
Heart rate effect	Dose-dependent elevation	Minimal
FDA approval	Investigational — NDA not filed (Jul 2026)	Approved June 2021 (obesity/weight management)
Titan RUO stock	Yes — lyophilized vial $199.99	No — not stocked

Questions researchers ask

Before you order.

What is the difference between retatrutide and Wegovy?: Wegovy is semaglutide (2.4 mg, Novo Nordisk), a selective GLP-1 receptor agonist FDA-approved for chronic weight management in adults with obesity. Retatrutide is an investigational triple agonist (Eli Lilly) that activates GIP, GLP-1, and glucagon receptors simultaneously. In Phase 3 data, the triple-receptor mechanism translates to approximately double the weight reduction: STEP-1 (Wegovy) ~14.9% at 68 weeks vs TRIUMPH-4 (retatrutide) ~28.7% at 68 weeks. They are different molecules in different regulatory stages. Research comparison only.
Is retatrutide stronger than Wegovy?: In terms of Phase 3 efficacy data at comparable timepoints, yes — TRIUMPH-4 (retatrutide, ~28.7% at 68 weeks) substantially exceeds STEP-1 (Wegovy, ~14.9% at 68 weeks). The mechanistic explanation is the additional GIP and glucagon receptor arms, which add insulin potentiation and thermogenesis on top of GLP-1R appetite suppression. However, Wegovy has years of real-world safety data across millions of patients; retatrutide's safety profile is still being characterized in Phase 3. This is a research-pharmacology comparison, not a clinical recommendation.
Can retatrutide replace Wegovy?: No — and this page does not suggest that. Wegovy is an FDA-approved prescription medication. Retatrutide is an investigational compound that Titan supplies as a research-use-only lyophilized vial for in-vitro laboratory research. They are in different regulatory categories and different supply channels. Any weight management treatment decision is a clinical matter between a patient and their prescribing physician.
Does Titan sell Wegovy?: No. Titan Peptide Lab does not stock semaglutide in any formulation (Ozempic, Wegovy, Rybelsus). Titan supplies retatrutide as a research-use-only lyophilized vial ($199.99) for laboratory research purposes. Wegovy is available as an FDA-approved prescription medication through licensed pharmacies and prescribers.
What comes after Wegovy — is retatrutide next?: From a pharmacology perspective, retatrutide represents the next generation of incretin receptor targeting beyond Wegovy: from single GLP-1R (semaglutide/Wegovy) to dual GLP-1R+GIPR (tirzepatide/Zepbound) to triple GLP-1R+GIPR+GcgR (retatrutide). As of July 2026, retatrutide Phase 3 results are announced and Eli Lilly has Breakthrough Therapy Designation, but no NDA has been filed. FDA approval timeline if pursued would be an additional 1–2 years. Titan supplies retatrutide now as an investigational research compound for in-vitro study only.